The traditional Chinese medicine sector has changed, and many stocks such as Special One Pharmaceutical and Zhongsheng Pharmaceutical have risen and stopped

【Pharmaceutical Network Pharmaceutical Stock Market】On November 9, the traditional Chinese medicine sector changed, and individual stocks were up and down, including many stocks such as Special One Pharmaceutical and Zhongsheng Pharmaceutical, as well as Yiming Pharmaceutical, Enwei Pharmaceutical, Huluwa, Kun Pharmaceutical Group, Dali Pharmaceutical, etc.
have followed
.
Special One Pharmaceutical was up and down during the session on November 9, and the stock has risen and stopped 9 times in
the past year.
As of 10:37, the stock was quoted at 17.
41 yuan, with a turnover of 367 million, a turnover rate of 14.
35%, and a price-to-earnings (TTM) of 31.
68
。 For the reasons for the change in the stock, the analysis believes that there are several aspects: the company is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and chemical raw materials; Its cephalexin capsules have passed the consistency evaluation of generic drugs, and the product is one of the key products of anti-infective drugs, mainly used for the treatment of acute tonsillitis, angina, sinusitis, bronchitis, pneumonia and other respiratory tract infections, otitis media, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria; The company's cough tablets products have a long history of nearly 100 years, and the secret recipe of the product has been selected as the cultural protection heritage
of Lingnan traditional Chinese medicine.
In addition, the company plans to invest 100 million yuan to establish Guangdong Temei Health Technology Industry Co.
, Ltd.
, which is the big health industry investment and operation platform of Teyi Pharmaceutical Group, and its development direction includes the development and investment
in the field of medical cosmetology services.
Zhongsheng Pharmaceutical also touched the limit on November 9, as of 10:37, the stock was quoted at 32.
18 yuan, with a turnover of 2.
361 billion, a turnover rate of 10.
69%, and a price-to-earnings (TTM) of 123.
28
.
The company issued a change announcement on October 8, regarding a randomized, double-blind, placebo-controlled phase III clinical study protocol of RAY1216, which has obtained the rapid review approval of the clinical trial of the Medical Ethics Committee of the First Affiliated Hospital of Guangzhou Medical University, the team leader, and approved the project to be carried out
。 In view of the long cycle and large investment of clinical trial research, there are risks that the promotion of R&D projects and the R&D effect do not meet expectations, and the clinical trial progress, review and approval results of innovative drugs, and the future product market competition pattern have certain uncertainties.
There is uncertainty
as to whether drugs can be approved for marketing, when they will be approved for marketing, and the production and sales after marketing.
On the news, the State Food and Drug Administration recently held an expert advisory committee
on strategic decision-making on the management of traditional Chinese medicines.
The meeting pointed out that since the beginning of this year, the efficiency of Chinese medicine review and approval has been significantly improved, and the Chinese medicine supervision system has been sound and optimized
.
It will accelerate the construction of a scientific system for the supervision of traditional Chinese medicines, and promote the inheritance and innovation and development of traditional Chinese medicines; Vigorously develop scientific research on the supervision of traditional Chinese medicines, and accelerate the modernization of
the governance system and governance capacity of traditional Chinese medicines.
The analysis believes that the efficiency of Chinese medicine review and approval has been significantly improved, injecting a "strong needle" into the development of Chinese medicine, and driving the Chinese medicine sector to rise
again.
For the future market, many securities institutions expressed optimism about the future market of
the Chinese medicine sector.
For example, Soochow Securities said in the research report that in recent years, from top-level design to specific measures, the state has introduced a number of policies to encourage the development of traditional Chinese medicine, especially in the past two years, including medical insurance payment, optimization of review and approval rules, encouragement of traditional Chinese medicine innovation and talent development and other traditional Chinese medicine policies have been intensively introduced, which fully shows that China attaches importance to and supports
the inheritance and innovation of traditional Chinese medicine 。 Donghai Securities also expressed its optimism about Chinese medicine, believing that in the future, with the increase in the penetration rate of Chinese medicine services in diagnosis and treatment and the embodiment of the prevention and treatment effect in the field of preventive treatment, the culture and concept of Chinese medicine will be more widely disseminated among the population, so as to increase the frequency of use of Chinese medicine diagnosis and treatment solutions and Chinese medicine products, which is conducive to the long-term development of
Chinese medicine.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice
to anyone.